v3.22.4
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net loss $ (151,528) $ (109,559)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 24,750 22,381
Depreciation on property and equipment 139 87
Non-cash lease expense 844 831
Changes in operating assets and liabilities:    
Accounts receivable 11,762 (7,918)
Prepaid expenses and other current assets (14,297) 4,109
Accounts payable (4,495) 1,383
Accrued expenses 1,278 16,188
Operating lease liabilities (853) (658)
Net cash used in operating activities (132,400) (73,156)
Cash flows from investing activities    
Purchase of property and equipment (171) (136)
Net cash used in investing activities (171) (136)
Cash flows from financing activities    
Payment of offering costs (272) 0
Proceeds from stock options exercised 424 0
Capital contributions 0 129
Net cash provided by financing activities 70,652 200,129
Effect of exchange rate changes on cash and cash equivalents 710 20
Net change in cash and cash equivalents (61,209) 126,857
Cash and cash equivalents – beginning of period 493,817 400,146
Cash and cash equivalents – end of period 432,608 527,003
Underwritten Offering    
Cash flows from financing activities    
Proceeds from issuance of common stock upon underwritten offering 70,500 0
Proceeds from investment by Roivant Sciences Ltd. 70,500 0
Roivant Sciences Ltd. (RSL)    
Cash flows from financing activities    
Proceeds from issuance of common stock upon underwritten offering 0 200,000
Proceeds from investment by Roivant Sciences Ltd. $ 0 $ 200,000